NDC 0078-0911

Xiidra

Lifitegrast

Xiidra is a Ophthalmic Solution/ Drops in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Lifitegrast.

Product ID0078-0911_1de81040-6b02-4632-afec-bde1e05391da
NDC0078-0911
Product TypeHuman Prescription Drug
Proprietary NameXiidra
Generic NameLifitegrast
Dosage FormSolution/ Drops
Route of AdministrationOPHTHALMIC
Marketing Start Date2016-07-11
Marketing CategoryNDA / NDA
Application NumberNDA208073
Labeler NameNovartis Pharmaceuticals Corporation
Substance NameLIFITEGRAST
Active Ingredient Strength50 mg/mL
Pharm ClassesLymphocyte Function-Associated Antigen-1 Antagonist [EPC],Lymphocyte Function-Associated Antigen-1 Antagonists [MoA]
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 0078-0911-12

12 POUCH in 1 CARTON (0078-0911-12) > 5 AMPULE in 1 POUCH (0078-0911-05) > .2 mL in 1 AMPULE
Marketing Start Date2020-06-04
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Xiidra" or generic name "Lifitegrast"

NDCBrand NameGeneric Name
0078-0911XiidraLifitegrast
54092-606XiidraLifitegrast

Trademark Results [Xiidra]

Mark Image

Registration | Serial
Company
Trademark
Application Date
XIIDRA
XIIDRA
87319276 5271076 Live/Registered
SARcode Bioscience Inc.
2017-01-31
XIIDRA
XIIDRA
86056637 5050074 Live/Registered
SARcode Bioscience Inc.
2013-09-05
XIIDRA
XIIDRA
79293316 not registered Live/Pending
NOVARTIS AG
2020-06-29

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.